These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 20696179)
1. Occupancy of human brain GABA(A) receptors by the novel α5 subtype-selective benzodiazepine site inverse agonist α5IA as measured using [¹¹C]flumazenil PET imaging. Eng W; Atack JR; Bergstrom M; Sanabria S; Appel L; Dawson GR; Sciberras D; Hargreaves RJ; Langstrom B; Burns HD Neuropharmacology; 2010 Dec; 59(7-8):635-9. PubMed ID: 20696179 [TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonist. Atack JR; Maubach KA; Wafford KA; O'Connor D; Rodrigues AD; Evans DC; Tattersall FD; Chambers MS; MacLeod AM; Eng WS; Ryan C; Hostetler E; Sanabria SM; Gibson RE; Krause S; Burns HD; Hargreaves RJ; Agrawal NG; McKernan RM; Murphy MG; Gingrich K; Dawson GR; Musson DG; Petty KJ J Pharmacol Exp Ther; 2009 Nov; 331(2):470-84. PubMed ID: 19704033 [TBL] [Abstract][Full Text] [Related]
3. Preclinical and clinical pharmacology of the GABAA receptor alpha5 subtype-selective inverse agonist alpha5IA. Atack JR Pharmacol Ther; 2010 Jan; 125(1):11-26. PubMed ID: 19770002 [TBL] [Abstract][Full Text] [Related]
4. The plasma-occupancy relationship of the novel GABAA receptor benzodiazepine site ligand, alpha5IA, is similar in rats and primates. Atack JR; Eng WS; Gibson RE; Ryan C; Francis B; Sohal B; Dawson GR; Hargreaves RJ; Burns HD Br J Pharmacol; 2009 Jul; 157(5):796-803. PubMed ID: 19422390 [TBL] [Abstract][Full Text] [Related]
5. GABAA receptor subtype-selective modulators. II. α5-selective inverse agonists for cognition enhancement. Atack JR Curr Top Med Chem; 2011; 11(9):1203-14. PubMed ID: 21050171 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological evaluation of 3-heterocyclyl-7,8,9,10-tetrahydro-(7,10-ethano)-1,2,4-triazolo[3,4-a]phthalazines and analogues as subtype-selective inverse agonists for the GABA(A)alpha5 benzodiazepine binding site. Street LJ; Sternfeld F; Jelley RA; Reeve AJ; Carling RW; Moore KW; McKernan RM; Sohal B; Cook S; Pike A; Dawson GR; Bromidge FA; Wafford KA; Seabrook GR; Thompson SA; Marshall G; Pillai GV; Castro JL; Atack JR; MacLeod AM J Med Chem; 2004 Jul; 47(14):3642-57. PubMed ID: 15214791 [TBL] [Abstract][Full Text] [Related]
7. Specific targeting of the GABA-A receptor α5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice. Braudeau J; Delatour B; Duchon A; Pereira PL; Dauphinot L; de Chaumont F; Olivo-Marin JC; Dodd RH; Hérault Y; Potier MC J Psychopharmacol; 2011 Aug; 25(8):1030-42. PubMed ID: 21693554 [TBL] [Abstract][Full Text] [Related]
8. In vivo characterization and dynamic receptor occupancy imaging of TPA023B, an alpha 2/alpha 3/alpha 5 subtype selective gamma-aminobutyric acid-a partial agonist. Van Laere K; Bormans G; Sanabria-Bohórquez SM; de Groot T; Dupont P; De Lepeleire I; de Hoon J; Mortelmans L; Hargreaves RJ; Atack JR; Burns HD Biol Psychiatry; 2008 Jul; 64(2):153-61. PubMed ID: 18339360 [TBL] [Abstract][Full Text] [Related]
9. Benzodiazepine binding site occupancy by the novel GABAA receptor subtype-selective drug 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in rats, primates, and humans. Atack JR; Wong DF; Fryer TD; Ryan C; Sanabria S; Zhou Y; Dannals RF; Eng WS; Gibson RE; Burns HD; Vega JM; Vessy L; Scott-Stevens P; Beech JS; Baron JC; Sohal B; Schrag ML; Aigbirhio FI; McKernan RM; Hargreaves RJ J Pharmacol Exp Ther; 2010 Jan; 332(1):17-25. PubMed ID: 19779131 [TBL] [Abstract][Full Text] [Related]